publication date: Mar. 30, 2017

Lung Cancer Proton therapy offers treatment possibility for recurrent lung cancer

A new study offers a treatment option for patients with recurrent lung cancer, who historically have been considered ineligible for curative treatment.

In the largest analysis to date of reirradiation using intensity-modulated proton therapy for lung and other thoracic tumors, more than three-fourths of patients were free from local recurrence at one year following retreatment, and fewer than one in ten patients experienced severe side effects.

The study will be presented today at the 2017 Multidisciplinary Thoracic Cancers Symposium. Lung cancer causes more deaths in the United States than any other type of cancer, due in part to its aggressive nature and likelihood of recurrence. Historically, recurrences have been challenging to treat, because many of these patients are not candidates for surgery.

Moreover, concerns about cumulative radiation doses to essential organs near thoracic tumors (e.g., heart, lungs, esophagus) may limit the use of curative radiation therapy for patients who received thoracic RT in the past. Accordingly, patients whose lung cancer recurs are generally offered only palliative options to manage pain and other symptoms.

Proton therapy, an advanced type of RT, allows radiation oncologists to spare critical normal tissues while delivering escalated, curative doses of radiation to nearby tumors. In particular, IMPT is able to exactly target a tumor, even if the … Continue reading CCL March 2017 – Proton therapy offers treatment possibility for recurrent lung cancer

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.